2024
Racial and ethnic disparities in diagnosis and treatment outcomes among US-born people diagnosed with tuberculosis, 2003–19: an analysis of national surveillance data
Regan M, Li Y, Swartwood N, Barham T, Asay G, Cohen T, Hill A, Horsburgh C, Khan A, Marks S, Myles R, Salomon J, Self J, Menzies N. Racial and ethnic disparities in diagnosis and treatment outcomes among US-born people diagnosed with tuberculosis, 2003–19: an analysis of national surveillance data. The Lancet Public Health 2024, 9: e47-e56. PMID: 38176842, DOI: 10.1016/s2468-2667(23)00276-1.Peer-Reviewed Original ResearchConceptsNational surveillance dataNon-Hispanic White peopleTreatment outcomesEthnic disparitiesSurveillance dataTuberculosis diagnosisUS National Tuberculosis Surveillance SystemIndex of disparityLog-binomial regression modelsNational Tuberculosis Surveillance SystemNon-Hispanic black peopleOverall high riskTuberculosis Surveillance SystemAlaska Native peopleTuberculosis patientsDiagnostic delayAdverse outcomesTuberculosis diseaseTuberculosis incidence
2021
Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae
Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. The Lancet Global Health 2021, 9: e1679-e1687. PMID: 34798027, PMCID: PMC8609280, DOI: 10.1016/s2214-109x(21)00367-3.Peer-Reviewed Original ResearchConceptsPost-tuberculosis sequelaeBurden estimatesTuberculosis diseaseDisease episodesIncident tuberculosisIncident tuberculosis casesIncident tuberculosis diseaseNon-fatal health lossOverall disease burdenPulmonary tuberculosis diseaseLifetime health outcomesDisease burden estimatesElevated mortality riskHigh incidence rateExtrapulmonary diseaseLung functionCase fatalityHIV statusLifetime burdenTuberculosis casesTotal DALYsDisease burdenIncidence rateHypothetical cohortTuberculosis survivorsThe Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease
Menzies NA, Shrestha S, Parriott A, Marks SM, Hill AN, Dowdy DW, Shete PB, Cohen T, Salomon JA. The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology 2021, 33: 75-83. PMID: 34669631, PMCID: PMC8633045, DOI: 10.1097/ede.0000000000001418.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh positive predictive valueFuture tuberculosisLatent tuberculosis infection treatmentIncremental costHigher treatment initiationCompletion of treatmentInterferon-gamma releaseQuality-adjusted life yearsTransmission dynamic modelLTBI testingTreatment initiationTreatment acceptanceTuberculosis diseasePrevention servicesPredictive valueTreatment servicesLife yearsTuberculosisInfection treatmentSocietal perspectiveIGRATreatment volumeHealth improvementFuture progression
2019
Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study
Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. The BMJ 2019, 367: l5894. PMID: 31649017, PMCID: PMC6812583, DOI: 10.1136/bmj.l5894.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntitubercular AgentsChildChild, PreschoolContact TracingDisease ProgressionFemaleFollow-Up StudiesHumansIncidenceInfantInfant, NewbornIsoniazidKaplan-Meier EstimateMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPeruProspective StudiesRifampinSputumTuberculin TestTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryYoung AdultConceptsDrug-sensitive tuberculosisMultidrug-resistant tuberculosisHousehold contactsProspective cohort studySensitive tuberculosisTuberculosis infectionResistant tuberculosisCohort studyTuberculosis diseaseHigh riskDrug-resistant Mycobacterium tuberculosisIncident tuberculosis diseasePhenotypic drug resistanceDistrict Health CenterResistant Mycobacterium tuberculosisDrug-susceptible strainsDrug resistance profilesActive diseasePulmonary tuberculosisDisease progressionGuideline producersHealth centersIndex patientsEffective treatmentPatients
2014
Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates
Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Pérez-Vélez CM, Pagano M, Becerra MC, Cohen T. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. The Lancet 2014, 383: 1572-1579. PMID: 24671080, PMCID: PMC4094366, DOI: 10.1016/s0140-6736(14)60195-1.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMultidrug-resistant tuberculosis diseaseTreatment-naive adultsMultidrug-resistant diseaseTuberculosis diseaseTuberculosis incidenceGlobal incidenceSystematic reviewCases of tuberculosisHarvard Medical SchoolGlobal tuberculosis incidenceGlobal annual incidenceTuberculosis riskAnnual incidencePatient groupUS National InstitutesWomen's HospitalInclusion criteriaInternal medicineNew diagnostic instrumentDisease riskTuberculosisIncidenceDiseaseHealth equity
2013
Isoniazid-resistant Tuberculosis in Children
Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant Tuberculosis in Children. The Pediatric Infectious Disease Journal 2013, 32: e217-e226. PMID: 23348808, PMCID: PMC3709006, DOI: 10.1097/inf.0b013e3182865409.Peer-Reviewed Original ResearchConceptsIsoniazid-resistant tuberculosisLatent tuberculosis infectionTuberculosis diseaseTuberculosis infectionIsoniazid resistancePediatric tuberculosis patientsTreatment of childrenIsoniazid-resistant strainsReports of childrenEffective regimensTuberculosis patientsTuberculosis treatmentAppropriate treatmentInclusion criteriaMedian proportionSystematic reviewRifampin resistanceDiseaseTuberculosisRegimensChildrenTreatmentInfectionIsoniazidHigher proportion
2011
Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure
Mills HL, Cohen T, Colijn C. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. Journal Of The Royal Society Interface 2011, 8: 1510-1520. PMID: 21508012, PMCID: PMC3163428, DOI: 10.1098/rsif.2011.0160.Peer-Reviewed Original ResearchConceptsTB diseaseLatent M. tuberculosis infectionEffects of IptHIV-endemic settingsActive tuberculosis diseaseIsoniazid preventive therapyIntact immune systemM. tuberculosis infectionWorld Health OrganizationPreventive therapyTB casesTuberculosis infectionTuberculosis diseaseClinical trialsEndemic settingsIPT programHigh riskLatent infectionSingle drugCommunity-wide levelRespiratory contactHIVImmune systemPopulation-level impactUse of IPT
2006
Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission
Cohen T, Colijn C, Finklea B, Murray M. Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. Journal Of The Royal Society Interface 2006, 4: 523-531. PMID: 17251134, PMCID: PMC2373405, DOI: 10.1098/rsif.2006.0193.Peer-Reviewed Original ResearchConceptsTB control strategiesPublic health policy makersType of TBMolecular epidemiologic toolsHealth policy makersTB diseasePrimary diseasePrimary progressionTB incidenceRecent infectionTB transmissionTuberculosis diseaseInfectious disease transmissionTuberculosis epidemicRecent transmissionEpidemiological dataForce of infectionInfectious casesLatent infectionEpidemiologic toolInfectionMycobacterium tuberculosisSpecific populationsDiseaseEpidemic trajectories